Sun Pharma Advanced Research Sheds Rs. 970 Crore In Nine Sessions As Rekha Jhunjhunwala Trims Stake
Sun Pharma Advanced Research Sheds Rs.970 Crore in Nine Sessions as Rekha Jhunjhunwala Trims Stake
Sun Pharma Share Price Advanced Research Company (SPARC) continued their downward trend, hitting a 52-week low of Rs.128.35 on February 18, with a 6.3% drop. The stock has declined 19% over the last nine sessions, erasing Rs.970 crore in market value.
Investor sentiment weakened further as Rekha Jhunjhunwala reduced her stake to 1.6% in Q3 from 1.9% in Q2. SPARC reported Rs.76 crore in revenue for FY24 but posted a net loss of Rs.387 crore, marking its eighth consecutive loss-making year.
Sun Pharma Advanced Research Company (SPARC) reduced its net loss to Rs.79.5 crore in Q3 FY24, improving from Rs.99.6 crore in the same period last year. Revenue for the quarter rose 7.6% to Rs.15 crore.
As of December 2024, promoters held nearly 55% of SPARC, with Shanghvi Finance owning 42.3% and Dilip Shanghvi 19.1%. Rekha Jhunjhunwala held a 1.6% stake.
Trading volumes surged on Tuesday, with nearly 12 lakh shares traded—double the 30-day average. SPARC stock has dropped 35.2% in 2025 after a 30% decline last year.
